More off-label drug promotion in the offing

You are here: Planet Chiropractic > News > Article

Serving Chiropractors Worldwide

Chiropractic Jobs | Practices for Sale | Employment | Billing Services

Search:

Posted on: Thursday, August 19, 1999

More off-label drug promotion in the offing
Dr. Mike

Though the full impact of a recent federal court ruling is unclear, doctors can expect more off-label drug use information from drug manufacturers.

Washington -- Eli Lilly announced this month that it would direct its sales representatives to market its osteoporosis drug, Evista (raloxifene), as a breast cancer prevention agent.
This step was noteworthy for two reasons. First, Evista so far has gained Food and Drug Administration marketing approval only for its osteoporosis indication. Second, a July court order barred the company from promoting the off-label breast cancer prevention use.

Source: American Medical News
Go There(Click to read the entire article)

Subscribe RSS:

E-mail newsletters

Search:

Select Featured Articles

Chiropractic Los Angeles:
What it's like

Featured Article - Chiropractor Salaries

Assessing
Chiropractor Salaries

Pregnancy &
Chiropractic

Estrogen, Hormones,
Osteoporosis and Bones

Copyright © 2000 - 2012 Planet Chiropractic. All rights reserved. The content (including but not limited to text, photo,
multimedia information, etc) published on this site belongs to Planet Chiropractic (planetc1,LLC). Without written
authorization from planetc1,LLC, such content shall not be republished or used in any form.
Questions or Comments - Privacy Policy - Terms of Service